BOSTON, MA, Pheon Therapeutics (Pheon), an Antibody-Drug Conjugate (ADC) specialist, launched following the closing of a $68 million Series A financing.
Pheon Therapeutics (Pheon), an Antibody-Drug Conjugate (ADC) specialist developing next generation ADCs for a wide range of hard-to-treat cancers, launched following the closing of a $68 million Series A financing in March 2022.
The financing was led by Brandon Capital, Forbion and Atlas Venture, with participation from seed investor Research Corporation Technologies (RCT).
(c) by Massinvestor, Inc. For contact info, please check out our
about page.
